Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea

Jun Ho Yi, Gyeong Won Lee, Ji Hyun Lee, Kwai Han Yoo, Chul Won Jung, Dae Sik Kim, Jeong Ok Lee, Hyeon Seok Eom, Ja Min Byun, Youngil Koh, Sung Soo Yoon, Jin Seok Kim, Jee Hyun Kong, Ho Young Yhim, Deok Hwan Yang, Dok Hyun Yoon, Do Hyoung Lim, Won Sik Lee, Ho Jin Shin

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Background Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries but is rare in the East Asian countries. Due to its rarity and the lack of feasible novel agents and laboratory prognostic tools, there are limited data on the clinical outcomes of this disease in Asia. To clarify the current treatment status, we performed a multicenter retrospective analysis of patients with CLL in Korea. Methods The medical records of 192 eligible patients between 2008 and 2019 were reviewed for clinical characteristics, treatment courses, and outcomes. The first-line treatment regimens of the patients included in this analysis were as follows: fludarabine/cyclophosphamide/rituximab (FCR) (N=117, 52.7%), obinutuzumab plus chlorambucil (GC) (N=30, 13.5%), and chlorambucil monotherapy (N=24, 10.8%). Results The median progression-free survival (PFS) was 55.6 months, and the average 2-year PFS rate was 80.3%. PFS was not significantly different between the patients receiving FCR and those receiving GC; however, chlorambucil treatment was associated with significantly inferior PFS (P <0.001). The median overall survival was 136.3 months, and the average 5- and 10-year OS rates were 82.0% and 57.4%, respectively. Conclusion This is one of the largest studies involving Korean patients with CLL. Although the patients had been treated with less favored treatment regimens, the outcomes were not different from those reported in Western studies.

Original languageEnglish
Pages (from-to)243-251
Number of pages9
JournalBlood Research
Issue number4
Publication statusPublished - 2021

Bibliographical note

Publisher Copyright:
© 2021 Korean Society of Hematology.

All Science Journal Classification (ASJC) codes

  • Hematology


Dive into the research topics of 'Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea'. Together they form a unique fingerprint.

Cite this